Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiparametric modulation of magnetic transduction for biomolecular sensing in liquids

  • Sanz-de-Diego, Elena
  • Aires, Antonio
  • Palacios-Alonso, Pablo
  • Cabrera, David
  • Silvestri, Niccolo
  • Vequi-Suplicy, Cinthia C.
  • Artés-Ibáñez, Emilio J.
  • Requejo-Isidro, José
  • Delgado-Buscalioni, Rafael
  • Pellegrino, Teresa
  • Cortajarena, Aitziber L.
  • Terán, Francisco J.
Electronic supplementary information (ESI) available. See DOI: https://doi.org/ 10.1039/d3nr06489a, The recent COVID19 pandemic has remarkably boosted the research on in vitro diagnosis assays to detect biomarkers in biological fluids. Specificity and sensitivity are mandatory for diagnostic kits aiming to reach clinical stages. Whilst the modulation of sensitivity can significantly improve the detection of biomarkers in liquids, this has been scarcely explored. Here, we report on the proof of concept and parametrization of a novel biosensing methodology based on the changes of AC magnetic hysteresis areas observed for magnetic nanoparticles following biomolecular recognition in liquids. Several parameters are shown to significantly modulate the transducing capacity of magnetic nanoparticles to detect analytes dispersed in saline buffer at concentrations of clinical relevance. Magnetic nanoparticles were bio-conjugated with an engineered recognition peptide as a receptor. Analytes are engineered tetratricopeptide binding domains fused to the fluorescent protein whose dimerization state allows mono- or divalent variants. Our results unveil that the number of receptors per particle, analyte valency and concentration, nanoparticle composition and concentration, and field conditions play a key role in the formation of assemblies driven by biomolecular recognition. Consequently, all these parameters modulate the nanoparticle transduction capacity. Our study provides essential insights into the potential of AC magnetometry for customizing biomarker detection in liquids., This work was partially funded by the Spanish State Research Agency (PCI2019-103600, CEX2020-001039-S, MDM-2017-0720, PID2019-111649RB-I00, PID2020-117080RB-C51, PID2020- 117080RB-C53, PID2019-111649RB-I00, PDC2021-120957-I00, PDC2022-133345-I00, and Hipernano, RED2018-102626-T, PTA2018-015076) and Comunidad de Madrid (PEJ-2017-AI/ BMD-7517, PEJ-2020-AI/IND-19394, NANOMAGCOST S2018/ NMT-4321). COST Actions CA17115 (MyWave) and CA17140 (Nano2Clinic) were also acknowledged. This work was partially supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie HeatnMof grant (GA No. 860942)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue

  • Maestro, David
  • Palanca, Ana R.
  • Soto, Helena
  • Llanera, I.
  • DeGrave, Alisa Nicole
  • Guedes, Gabriela
  • Oliveira, Guilherme Henrique de
  • Coelho Conceição, André Luiz
  • Mieites, Verónica
  • Icardo, Jose M.
  • Sánchez-Cano, Carlos
  • Conde, Olga M.
  • Lutz, Susanne
  • Cortajarena, Aitziber L.
  • Villar Ramos, Ana V.
Cardiac fibrosis is a key characteristic of heart failure. CTPR390, an experimental anti-fibrotic inhibitor targeting Hsp90, has shown success in animal models, but remains unexplored in human cardiac models. This study evaluated an engineered cardiac connective tissue (ECCT) model, focusing on changes in the extracellular matrix and fibroblasts. Results showed that CTPR390 prevented architectural changes in TGFβ1-activated ECCT, preserving tissue perimeter, collagen fibers alignment while reducing structured areas and degree of collagen structuration. CTPR390 treatment reduced cell area of fibroblasts under tension, without changes in the internal rounded cells devoid of tension. Fibroblast recruitment to tension areas was diminished, showing biomechanical behavior similar to control ECCT. This treatment also lowered the gene and protein expression of key pro-fibrotic markers. Here, advanced biotechnology was employed to detect the detailed structure of tissue fibrosis reduction after administering CTPR390, representing a significant advancement toward clinical application for cardiac fibrosis treatment., This work was partially supported by Agencia Estatal de Investigación (AEI/MCI/10.13039/501100011033), Spain. A.V.V. PID2021-125702OB-I00. Fomento de la transferencia de conocimiento en la Comunidad Autónoma de Cantabria SUBVTC-2023-0006 T. A.L.C. acknowledges support by the Agencia Estatal de Investigación Grant PDC2021-120957-I00-NanoIVD and PDC2022-133345-I00-ProIMAGE funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR” and Grant PID2022-137977OB-I00-ProTher funded by MCIN/AEI/ 10.13039/501100011033. C.S.C. thanks Gipuzkoa Foru Aldundia (Gipuzkoa Fellows program) Grant number 2019-FELL-000018-01/62/2019 for financial support. G.G. thanks the financial support of “la Caixa” Foundation (ID100010434, fellowship: LCF/BQ/DI20/11780020). This work was performed under the Maria de Maeztu Units of Excellence and Severo Ochoa Centers Programs from the Spanish State Research Agency – Grants No. MDM-2017-0720 (CIC biomaGUNE) and CEX2018-000867-S (DIPC). O.M.C. and V.M. thank the AEI for the infrastructure EQC 2019-006589-P and the PREVAL 21/07 grant from IDIVAL., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2018-000867-S)., Peer reviewed